Article

QLT lowers verteporfin cost after CMS cuts reimbursement

Toronto-QLT Inc. is temporarily lowering the price of verteporfin (Visudyne, Novartis and QLT Inc.) by $55 after the Centers for Medicare & Medicaid Services (CMS) lowered the amount for which it would reimburse physicians.

Related Videos
Vicki Chan, MD, shares pearls for leveraging the power of social media in health care
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
John Bladen, MBBS, BSc, MRCS, PGCert, PhD, FRCOphth, consultant ophthalmologist and oculoplastic surgeon, King's College Hospital NHS Foundation Trust, London, UK, speaks with Ophthalmology Times Europe's® Caroline Richards
rande, CFP, and John S. Grande, CFP, of Grande Financial Services, continue their discussion with Ophthalmology Times®' Sheryl Stevenson
Related Content
AAO 2024: One simple change to boost sustainability in eye clinics: Stop discarding eye drops before they expire
October 17th 2024

AAO 2024: One simple change to boost sustainability in eye clinics: Stop discarding eye drops before they expire

Commercial real estate and your practice, part two with Colin Carr
May 21st 2022

Commercial real estate and your practice, part two with Colin Carr

Mental health and ophthalmology
May 17th 2024

Mental health and ophthalmology

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)
May 12th 2022

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

Minimizing the carbon footprint of ophthalmic surgeries
Published: May 15th 2024 | Updated: May 20th 2024

Minimizing the carbon footprint of ophthalmic surgeries

Navigating disability insurance for ophthalmologists: Lessons learned
November 29th 2023

Navigating disability insurance for ophthalmologists: Lessons learned

© 2024 MJH Life Sciences

All rights reserved.